Another trial with promising future results is the EMPIRE-HF (Empagliflozin in heart failure patients with reduced ejection fraction) randomized, double-blinded, placebo-controlled, parallel group, clinical trial that randomized patients with HF with reduced left ventricular ejection fraction (≤40%) on optimal therapy, in either empagliflozin 10 mg daily or placebo with primary endpoint the effect on NT-proBNP [85]. The gene discussed is NPPB; the disease is hydrops fetalis.